Clinical trial
Belatacept to Prevent Organ Rejection in Kidney Transplant Patients
NCT00346151 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Terminated
Key facts
| NCT number | NCT00346151 |
|---|---|
| Title | Belatacept to Prevent Organ Rejection in Kidney Transplant Patients |
| Official title | The Safety and Efficacy of Belatacept, Antithymocyte Globulin, and Sirolimus in Recipients of Non-HLA-identical Living-donor Renal Transplants (ITN023ST) |
| Acronym | BESTT |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Immune Tolerance Network (ITN) |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Transplant |
| Intervention type | Drug |
| Interventions | Belatacept, Sirolimus, Anti-thymocyte globulin, methylprednisolone |
| Enrollment | 5 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 1, 2010 |
| First posted | Jun 29, 2006 |
| Last update posted | Apr 21, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: